

Rain Oncology to Participate in the 2023 Citi Virtual Oncology Leadership Summit

NEWARK, Calif., February 9, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), ("Rain"), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the p53-MDM2 complex that reactivates p53, today announced that Avanish Vellanki, Chief Executive Officer of Rain, will be participating in a fireside chat at the Citi Virtual Oncology Leadership Summit on Tuesday, February 21, 2023, at 12:00 p.m. ET, being held virtually.

A live webcast of the fireside chat can be accessed [here](#). A replay of the event will be available on the "[Events](#)" section of the Rain website after the conclusion of the event and will be archived on the Rain website at www.rainoncology.com.

About Rain Oncology Inc.

Rain Oncology Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors' underlying genetics rather than histology. Rain's lead product candidate, milademetan, is a small molecule, oral inhibitor of the p53-MDM2 complex that reactivates p53. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Media Contact

Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com

Investor Contact

Dan Ferry
LifeSci Advisors
+1.617.430.7576
daniel@lifesciadvisors.com